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Myeloid lineage skewing due to exacerbated NF-κB
signaling facilitates osteopenia in Scurfy mice
TH-P Chen1, G Swarnkar1, G Mbalaviele2 and Y Abu-Amer*,1

Immune surveillance through Foxp3+ regulatory T cells plays a crucial role in bone homeostasis. Scurfy, the mouse model of
autoimmune IPEX syndrome, bears a loss-of-function mutation in Foxp3 that leads to multi-organ inflammation. Herein, we report
that scurfy mice exhibit severe bone loss mediated by accelerated osteoclastogenesis. Mechanistically, Foxp3 deficiency results in
the upregulation of NF-κB in T helper cells through the loss of repressive Foxp3/NEMO interaction, thereby unleashing NF-κBmediated over-production of pro-osteoclastogenic cytokines. Flow cytometry analysis shows marked increase in lin-Sca-1+c-kit+
hematopoietic stem cells (LSK HSCs) and granulocyte/macrophage progenitors (GMPs) in bone marrow of scurfy mice with
corresponding exacerbated osteoclastogenic potential, implying that osteoclast progenitors are affected at a very primitive stage
in this disorder. Scurfy LSK HSCs exhibit greater sensitivity to M-CSF and contain abundant PU.1+ Sf LSK HSCs compared with
WT. Accordingly, genetic or pharmacological inhibition of M-CSF or mTOR signaling, but not IL-17 signaling, attenuates
osteoclastogenesis and osteopenia in scurfy. Thus, our study suggests that Foxp3 deficiency leads to osteopenia owing to
dysregulated NF-κB activity and subsequent cytokine-mediated hyper-proliferation of myeloid precursors, and positions the
NF-κB pathway as a potential target for therapeutic intervention for this disorder.
Cell Death and Disease (2015) 6, e1723; doi:10.1038/cddis.2015.87; published online 16 April 2015

Skeletal homeostasis is primarily controlled by bone-resorbing
osteoclasts and bone-forming osteoblasts.1 The former cells
originate from hematopoietic lineage and require M-CSF and
RANKL to differentiate into multi-nucleated bone-resorbing
cells.2,3 The differentiation factors are derived from several
sources, chiefly mesenchymal cells and activated T cells,
suggesting that bone homeostasis is regulated by various
systems, including the immune network. Regulatory T cells
(Tregs) are crucial for maintaining immune self-tolerance.4
The development and survival of these cells depend on the
expression of the transcription factor Foxp3.5 The functional
significance of this transcription factor in Tregs was recognized
in humans with immune dysregulation polyendocrinopathy
and enteropathy X-linked (IPEX) syndrome.6 These patients,
similar to scurfy (Sf) mice, lack Tregs owing to mutations in the
Foxp3 gene, which leads to the development of fatal
autoimmune hyper-proliferative disease.7 In contrast, forced
expression of Foxp3 alleviates autoimmune responses, such
as inflammatory bowel disease.7,8
T-cell immune regulation of skeletal homeostasis has been
widely studied owing to inflammatory bone disparities.9,10 The
initial direct evidence for such regulation was the identification
of T-cell-derived RANKL, the primary osteoclast differentiation
factor.11,12 Subsequent studies identified IL-17, product of
Th17 cells, as the principal potent cytokine that induces the
osteoclastogenic factors RANKL, IL-1 and tumor necrosis
factor α.13 On the other hand, strong evidence suggests that
1

Th-cell-derived IFNγ and IL-4 are potent inhibitors of
osteoclastogenesis.14 Likewise, potentiating Treg cells by
forced expression of Foxp3 increased bone mass in mice by
impairing osteoclast differentiation.15 However, additional
cellular and molecular details have been offered to describe
the mechanisms underlying T-cell regulation by Foxp3 and
suppression of osteoclastogenesis. In this regard, it was
reported that transcriptional (NFAT and NF-κB),16 cell–cell
interaction (via CTLA-4)17 and cytokine-dependent18 mechanisms contribute to this response.
To further elucidate the cellular and molecular mechanism
underlying T-cell regulation of osteoclast differentiation, we
examined the skeletal development of the Sf mouse in which
Treg differentiation and function are dysregulated owing to
Foxp3 mutation. Our findings show that the skeleton of Sf mice
deteriorates because of elevated osteoclastogenesis. This
phenomenon appears to be the result of increased frequency
of a myeloid sub-population, namely GMPs, that gives rise to
osteoclasts. The high frequency of these progenitors was
maintained by higher levels of M-CSF as depletion of this
factor reversed the osteoporotic bone phenotype. We further
provide evidence that these cellular changes are likely
subsequent to hyper-activation of NF-κB signaling in CD4+
T cells and GMPs, suggesting that Foxp3 is an endogenous
regulator of NF-κB-mediated inflammatory and osteoclastogenic
factors.
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Results
Sf mice exhibit bone loss. The effect of autoimmune
response in many organs of Sf mice has been extensively
studied.19 Given the pronounced inflammation-induced skeletal manifestations, we decided to investigate how lack of
immune surveillance by Tregs in Sf mice affects bone.
Bone morphometric and histological analyses on 4-week-old
Sf as well as wild type (WT) littermates show significant
reduction of bone volume in both trabecular (Figure 1a) and
cortical (Figure 1b, arrows) bones of Sf mice. Quantitative
analysis further indicated that all bone parameter changes

(Figures 1c–f) denote bone loss in Sf mice. TRAP staining of
histological sections of long (Figures 1g and h) and metatarsal
bones (Figures 1i and j) revealed increased marrow cellularity
(Figure 1i; asterisk) and elevated number of TRAP-positive cells
per bone surface area in Sf mice (Figures 1h and j), suggesting
that the bone loss phenotype of these mice is due to increased
numbers of osteoclasts and their progenitors. Indeed, we
established that Sf-derived whole bone marrow (WBM) cultures,
plated at similar cell density to WT in the presence of RANKL
and M-CSF, gave rise to increased number of osteoclasts
compared with WT cultures (Figures 1k and l), which was
also confirmed by semi-quantitative analysis of osteoclast

Figure 1 Sf mice exhibit severe bone loss and increased number of osteoclasts in bone. (a) Representative 3-D reconstructed images of the trabecular bone region in the
proximity to the growth plate were captured by μCT analysis. (b) Representative images of the proximal and midshaft cortex of the long bones are shown. (c–f) Quantification of
bone parameters: (c) μCT analysis depicts ratio of cancellous bone volume/tissue volume (BV/TV) in the same areas shown in panel a, (d) trabecular numbers (Tb N),
(e) trabecular separation (Tb Sp), (f) and trabecular thickness (Tb Th). (g–j) Histological examination of osteopenia in Sf mice. (g) Representative H&E- and TRAP-stained
histological section near the growth plate. (h) Quantifications of osteoclast number per surface area were plotted for the trabecular bone region. (i) Histological section of ankle
bones. (j) Quantifications of osteoclast number per surface area were plotted for the sections near the ankle region. (k) WBM cultures from WT and Sf mice were subjected to
vehicle or RANKL stimulation for 4 days before TRAP staining to visualize osteoclast formation. (l) Bar graphs were plotted by counting numbers of multi-nulceated (MNC) TRAP+
osteoclasts (OCs) from each of the 4 wells of each RANKL-stimulated groups. All bar graphs were depicted by the average of the numbers, ± S.D. Statistics: n = 4 per group;
*Po0.05 and **Po0.01 by Student T-test. Scale bars: 200 μm in (a), (i) and (k); 1 mm in (b); 100 μm in (g)
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marker expression (cathepsin K, MMP9 and β3 integrin)
(Supplementary Figure S1A).
NF-κB activation and over-production of proinflammatory
cytokines in Sf-derived T cells. The transcription factor
NF-κB is considered the master regulator of inflammatory
responses as it modulates the expression of a wide range of
inflammatory cytokines, besides being also essential for

osteoclastogenesis.20 We tested protein and mRNA expression of NF-κB genes, and found that the expression of
RelA/p65 and IKKγ/NEMO, the central modulators of NF-κB
signal transduction pathway, was predominately upregulated
2.1- and 5.6-fold for protein and 1.8- and 1.6-fold for
mRNA, respectively (Figure 2a and Supplementary Figures
S1B and S1C). Using intracellular flow assay, we found that
the proportion of NEMO-expressing cells was distinctively

Figure 2 Foxp3 deficiency in Sf mice resulted in the activation of NF-κB pathway and over-production of pro-osteoclast cytokines in CD4+ T lymphocytes. (a) Western blot of
NEMO and Rel A protein expression in splenic CD4+ T cells using WT and Sf-derived CD4+ T cells. Images shown were blots probed with anti-Rel A and anti-NEMO Ab
separately. β-actin was used as internal loading control. (b) Intracellular flow analysis was performed on red-cell-depleted WBMs. Cells were fixed, permeabilized and stained with
anti-NEMO Ab followed by FITC-conjugated secondary Ab and analyzed on flow cytometer. Histogram of the middle fluorescence intensity (MFI) of FITC was shown. (c) Coimmunoprecipitation of Foxp3 and NEMO protein in primary splenic CD4+T cells. CD4+T-cell proteins derived from WT and Sf pulled down by anti-NEMO Ab were blotted with
either anti-NEMO or anti-Foxp3 Ab. Total lysate from Foxp3+Tregs used as positive control. (d) Co-immunoprecipitation of Foxp3 and NEMO protein in transiently transfected
293 T cells. 293 T cells were transfected with both Foxp3 and NEMO (tagged with c-myc) plasmids. Cells transfected with either Foxp3 or NEMO plasmid alone were used as
controls. Immunoprecipitation (IP) and immunoblots (IB) were conducted as indicated. In addition, two clones of anti-Foxp3 Ab were used for IP, by which K-13 generated stronger
immunoprecipitation than H190. (e) qPCR analysis (fold change) of the indicated factors in MACS purified CD4+ T cells from WT and Sf mice. (f) Cytokine production following
PMA stimulation was assessed by intracellular flow analysis on MACS-purified, BM-derived CD4+ T cells using appropriate antibodies. (g) Intracellular flow analysis on MACSpurified, PMA-stimulated spleen-derived CD4+ T cells. (h) qPCR analysis (fold change) of M-CSF expression in MACS-purified, anti-CD3/CD28 stimulated CD4+ T cells from WT
and Sf mice. Bar graphs were depicted by the average of the numbers, ± S.D. Statistics for all bar graphs: n = 3 per group; *Po0.05 and **Po0.01 by Student T-test
Cell Death and Disease

Myeloid skewing leads to osteopenia in Scurfy mice
TH-P Chen et al

4

increased in Sf bone marrow (Figure 2b, solid line).
Further examination of NEMO-expressing cells by multicolor
flow cytometry revealed that a subset of myeloid cells
(CD11b+c-kit+) bore high NEMO expression (Supplementary
Figure S2A). In addition, analysis of NEMO-expressing cells
by CD11b and Gr1 resulted in the enrichment of CD11b+Gr1population by more than 2.5-fold (Supplementary Figure
S2B). These findings implied the importance of NEMO
upregulation in the myeloid proliferative disease in Sf mice.
Using co-immunoprecipitations from primary CD4+ cells (WT
and Sf) and from transiently transfected 293T cells, we show
that NEMO and Foxp3 physically interact (Figures 2c and d).
Further, using NF-κB reporter assay, Foxp3 protein was
able to suppress the reporter gene luciferase by 30%
(Supplementary Figure S3A). In addition, increased NEMO
expression was also found in the lymphoid tissues, including
lymph nodes and thymus, but not in the peritoneal cavity,
which was mostly comprised of macrophages (Supplementary
Figures S3B–S3F). We next tested mRNA expression
of pro-inflammatory/osteoclast cytokines in magnetically
isolated T helper (TH) cells. As shown in Figure 2e, RANKL,
M-CSF, IL-17 and tumor necrosis factor α were all found to be
upregulated in Sf-derived CD4+ TH cells, which were also
more activated than the WT cells as evidenced by increased
expression of the transcription factor NFAT. Intracellular flow
assay further confirmed that both bone marrow (Figure 2f)
and spleen-derived (Figure 2g), PMA/ionomycin-stimulated
CD4+ TH cells produced significantly higher levels of RANKL,
M-CSF and GM-CSF, with spleen (but not bone marrow)derived CD4+ TH cells also producing higher IL-17. Similarly,
when spleen-derived CD4+ TH cells were stimulated with
anti-CD3/CD28 antibody (Ab) beads, which is more physiologically relevant, we observed 48 × more expression of
M-CSF in Sf-derived cells compared with WT controls
(Figure 2h). Accordingly, multiplex ELISA showed elevated
serum levels of a wide range of chemokines, inflammatory
and growth factors in Sf mice compared with WT controls
(Supplementary Figure S4). Taken together, Foxp3 deficiency
resulted in the loss of Foxp3–NEMO interaction and led to the
overexpression of NEMO and subsequent activation of NF-κB
in TH cells. These pro-inflammatory cytokine-secreting T cells
were hyperactivated, thereby were suspected as culprit
inducers of higher osteoclastogenesis in Sf mice.
Enhanced myelopoiesis/myeloproliferative disease in the
Sf bone marrow leads to increased osteoclastogenic
potential. Next, we interrogated whether the increased
osteoclast burden and osteopenia in Sf mice is due to
skewed myelopoeisis secondary to hypercytokinemia.
Because osteoclasts differentiate from the myeloid lineage,
we hypothesized that dysregulation of lineage commitment or
differentiation of myeloid progenitor cells significantly contribute to increased osteoclastogenic potential of Sf bone
marrow. To test this, we performed flow cytometric analysis of
the myeloid compartment in the bone marrow, the spleen and
blood using monocytic marker CD11b and granulocytic
marker gr1. As shown in Figure 3a, the percentage of
monocytic CD11b+gr1-/lo cells was significantly increased in
bone marrow, whereas percentage of granulocytic
CD11b+gr1Hi cells was decreased. We further examined the
Cell Death and Disease

proliferative activity of Sf-derived cultures using BrdU flow
assay following 3 days of culture. Sf cultures exhibited nearly
twice of BrdU incorporation (Figures 3b and c) and proliferation of Sf cells was much faster than WT cells in the absence
(Supplementary Figure S5A) or presence of RANK ligand
(Supplementary Figure S5B). Taken together, increased
osteoclast formation in Sf mice is likely because of
hyperproliferative osteoclast precursor cells in Sf mice.
Through separating CD11bhi population from CD11blo after
lineage depletion (i.e., T and B cells, erythroid), we found that
CD11blo population exhibited far greater osteoclastogenesis
potential than CD11bhi population (Figure 3d). In addition,
CD11blo population isolated from Sf bone marrow possessed
hyperactive potency for osteoclastogenesis. In fact, almost an
equal level of osteoclast formation could be achieved by
plating 10 000 cells of CD11blo cells to 80 000 WBM cells
(Figure 3d; compare right with left panels, respectively). We
have also tested potential contribution of myeloid-derived
suppressor cells (MDSCs) to the Sf osteopenic bone
phenotype, as reported in murine breast cancer model,
wherein tumor-associated MDSCs, marked as CD11b+Gr-1+
cells,21 and MDSCs derived from murine inflammatory arthritis
model22 can be induced into osteoclasts. We found that Sf
bone marrow contained slightly less frequency of Gr-1hiLy6G+
MDSCs and much higher frequency of Gr-1dimLy6G- MDSCs
(Supplementary Figure S6A). However, both cell populations
exhibited poor osteoclastogenic potential (Supplementary
Figures S6B and C) as compared with WBM cultures
(Supplementary Figure S6D) and cell fractions devoid of the
two MDSC populations (Supplementary Figure S6E). Taken
together, although all immature myeloid cells were hyperproliferative in Sf compared with WT mice, only CD11blo/- cells
exhibited high osteoclastogenic potential.
Alteration of hematopoietic progenitor populations in Sf
mice. To test how the number of myeloid progenitor cells is
altered in Sf mice, we generated a comprehensive profile of
myeloid/osteoclast progenitors from the most primitive (i.e.,
long-term or LT-HSCs) to the more committed (i.e., GMPs)
cells.23 Frequency of the early lineage precursors lineagenegative, Sca-1-postive and c-kit-positive (LSK-HSCs) cells
was significantly elevated in Sf compared with WT mice
(Figure 4a). Among the more committed myeloid precursors,
frequency of GMPs derived from Sf bone marrow was twice
as much as from WT counterparts, whereas the frequency of
other progenitors was not significantly changed (Figure 4b).
Further characterization of LSKs by the SLAM marker
(CD150) revealed a significant increase for both short-term
HSC (ST-HSC) and mutipotent progenitor frequency, with
greater change for the latter (Figure 4c). Taken together,
these results suggested that under the inflammatory condition of Sf bone marrow, myelopoiesis was skewed toward
granulocyte/macrophage lineage. The primitive hematopoietic progenitor cells at the stage as early as the ST-HSCs
respond to the inflammatory cues by moving from quiescence
to active cell division, resulting in increasing numbers of
myeloid/osteoclast precursors. This phenomenon appeared
to be lineage-specific, as GMP frequency observed in Sf
bone marrow did not seem to be at the expense of
megakaryocyte/erythroid progenitors.
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Figure 3 Bone marrow CD11b-, not CD11b+, cells from Sf are highly proliferative and osteoclastogenic. (a) Flow analysis was performed on bone marrow myeloid
populations from 12 Sf and 11 WT controls stained with anti-CD11b and anti-Gr1 antibodies. Statistics was generated by Student T-test. (b) BrdU incorporation in Sf WBM
cultures was carried out as described under methods. (c) Bar graph derived from BrdU flow assays shown in panel b. n = 4 per group; *Po0.05 by Student
T-test. (d) MACS was performed first with biotin-conjugated lineage antibodies and anti-biotin microbeads followed by anti-CD11b microbeads to obtain lin-CD11b-/lo and
lin-CD11bHi fractions. Osteoclatogenic potential of each MACS fraction was subsequently tested by ex vivo osteoclastogenesis assay. WBM cultures were used as control.
Scale bars: 200 μm in (d)

Sf LSK HSCs are potent osteoclast founder cells.
Although the number of osteoclast progenitors is significantly
higher in Sf, the osteoclastogenic potential of each progenitor
cell may be also exacerbated. Hence, we examined whether
myeloid progenitors derived from Sf mice possess higher
'osteoclast founder' potential. Therefore, we FACS-sorted
lin-c-kit+CD11blogr-1lo cells (MPs) and LSK cells from WT and
Sf mice (Supplementary Figure S7) and combined equal
number of each cell population them with total bone marrow
cells from WT at the ratio of 1 : 10 (Figure 5) or 1 : 5 (not
shown) to make the culture with 10 000 and 5000 cells per
well density, without or with RANKL. Total bone marrow
cultures served as controls. As shown in Figure 5, WTderived LSKs supplemented with WT WBMs resulted in a
mild increase of osteoclastogenic potential, whereas Sfderived LSKs supplemented with WT WBMs exhibited higher
osteoclastogenic potential comparable with Sf WBMs. These
data indicate that Sf LSK HSCs were indeed highly potent
'founders' for osteoclastogenesis. Together, these findings
indicate that the ontology of increased osteoclastogenic
potential came at an early and primitive stage of differentiation
and commitment of Sf BM HSCs.

Inhibition of M-CSF significantly rescued bone erosion in
Sf mice. At the mechanistic level, this observation correlates
with a recent report suggesting that HSCs can be a direct
target for cytokine signaling.24 We reasoned that Sf-derived
HSCs might be hypersensitive to M-CSF, one of the essential
cytokines for osteoclast development. LSK HSCs were
FACS-sorted, plated for osteoclastogenesis assay at 2000
cells per well and stimulated with serial concentrations of
M-CSF. As shown in Supplementary Figure S8A, Sf -derived
LSKs responded to M-CSF in a much greater manner than
the WT controls. Furthermore, detection of PU.1 (which is the
target of M-CSF signaling and crucial for osteoclastogenesis)
expression in LSKs via intracellular flow revealed that its
protein level is significantly increased in Sf LSKs
(Supplementary Figure S8B), confirming the activation of
M-CSF signaling cascade in these progenitor cells.
To investigate the contribution of M-CSF hyper-production in
osteo-pathogenesis of Sf mice, we administrated M-CSFneutralizing Ab or carrier solution into Sf mice and WT male
siblings for 2 weeks. As expected, WT mice exhibited
osteopetrosis upon anti-MCSF Ab treatment assessed by
μCT analysis (Figure 6a). Interestingly, anti-M-CSF Ab-treated
Cell Death and Disease
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Figure 4 Alteration of hematopoietic progenitor pool in Sf bone marrow. (a, b) Flow cytometry of HSC progenitors was performed as described in Material and Methods.
Percentage of LSK hematopoietic progenitor cells were first gated and analyzed, followed by further sub-gating of the lin-c-kit+ cell population (LK) into megakaryocyte/erythroid
progenitors/CMP/GMPs. (c) LT-HSC, ST-HSCs and mutipotent progenitors were sub-gated from LSKs for analysis. Bar graphs were depicted by the average of the numbers,
± S.D. Statistics for all bar graphs: n = 6 for WT group and n = 7 for Sf group; *Po0.05 and **Po0.01 by Student T-test

Sf mice also developed increased BV/TV value comparable
with WT mice. Ex vivo osteoclastogenesis assay further
demonstrated the rescue of osteopenia/hyper-osteoclastogenesis in Sf via M-CSF neutralization (Figure 6b). In fact,
osteoclastogenesis derived from anti-MCSF-treated Sf mice
was reduced to levels comparable with that derived from WT
mice (Figure 6b; right panel). Interestingly, as anti-M-CSF Ab
treatment significantly reduced the frequency of LSKs in Sf
bone marrow, the frequencies of GMPs and mutipotent
progenitors were moderately decreased (Figure 6c and
Supplementary Figure S9). In addition, ex vivo osteoclastogenesis of Sf WBMs post M-CSF Ab treatment was
significantly blocked.
M-CSF haploinsufficiency significantly rescued the
osteopenic phenotype of Sf mice. To further address the
contribution of M-CSF signaling in the osteopenic phenotype
of Sf, we crossed Sf hemizygous female (Sf/x) with Op
heterozygous (Op/+) male to generate Op/+::Sf mice and
asked how osteoclast progenitors derived from Sf
would respond to M-CSF happloinsufficiency. As shown in
Figure 7a, μCT analysis revealed that introduction of one
Cell Death and Disease

op allele in Sf mice (i.e., Op/+, Sf/y) was able to bring the
trabecular BV/TV value equivalent to the WT control. In
addition, WBMs derived from Op/+::Sf mice only gave rise to
half osteoclast formation in number as compared with cells
derived from Sf alone (Figure 7b). Interestingly, although the
frequency of LSK HSCs did not change significantly
(Figure 7c), frequency of CMPs and GMPs were reduced in
Op/+::Sf (Figure 7d), suggesting that commitment or fate
determination of HSCs in Sf bone marrow was altered by
haploinsufficiency of M-CSF, resulting in attenuation of hyperosteoclastogenic activity.
To probe the therapeutic value of targeting M-CSF, we
tested whether blocking mTOR signaling (which is downstream M-CSF) would counteract the osteopenic disease in Sf
mice. Indeed, following 2 weeks of intraperitoneal rapamycin
injections, bone parameter of rapamycin-treated Sf mice
was comparable with that of vehicle-treated WT controls
(Figures 8a and b). Consistently, in vivo rapamycin treatment
reduced osteoclastogenesis activity of Sf-derived bone
marrow cells by almost twofold (Figure 8c). Interestingly, the
frequency of GMP in Sf BM was significantly reduced to
the level as in vehicle-treated WT controls (Figure 8d).

Myeloid skewing leads to osteopenia in Scurfy mice
TH-P Chen et al

7

Figure 5 Sf LSK HSCs are potent osteoclast founders. One thousand FACSsorted LSK and MPs (lin-c-kit+CD11blo described in Supplementary Figure S4) from
WT and Sf bone marrows and mixed with 9000 total bone marrow cells from WT and
treated with RANKL. WBM cultures were used as control. Bar graph was depicted by
the average of OC numbers, ± S.D. Statistics; n = 3 per group; *Po0.05 and
**Po0.01 by Student T-test. Scale bar: 200 μm

Taken together, inhibition of mTOR pathway appeared to an
effective approach on ameliorating Sf’s osteopenic phenotype.
Discussion
In this study, we report severe osteopenia in Sf mice
subsequent to the action of Foxp3-deficient lymphocytes.
Mechanistically, we provide evidence that Foxp3 deficiency
leads to enhanced activity of NF-κB, exemplified by elevated
expression of RelA/p65 and NEMO, the scaffold and regulator
of NF-κB signaling. As a result, numerous osteotropic and
osteoclastogenic factors are produced, which mobilize
hematopoietic progenitors pools, culminating with hypermyeloproliferation of osteoclast progenitors, exacerbated
osteoclastogenesis and osteopenia.
In recent years, several reports have suggested that Treg
cells play an inhibitory role in osteoclast formation.25,26 These
studies focused on the interaction between Treg cells and
osteoclast precursors, either through direct cell–cell contact or
paracrine mechanisms. In this report, we provide evidence
that lack of immune surveillance, due to Treg cell defeciency,
leads to hyperactivation of effector immune cells. Specifically,
we identified exuberant expression of RelA/p65 and NEMO
as markers of hyperactivated NF-κB in pro-inflammatory
cytokine-producing T effector (Foxp3-deficient) cells. Subsequently, production of pro-inflammatory cytokines is enhanced
and in turn stimulates repopulation and/or renewal of
hematopoietic progenitors. The cytokines produced by the
T effector cells directly target hematopoietic stem cell pools
and accelerate proliferation, mobilization and differentiation of
myeloid progenitors into osteoclasts. This is further evident by
the activation of NF-κB in OC progenitors, which is a crucial

osteoclastogenic factor. Indeed, inhibition of NF-κB signaling
by administration of NBD peptide halted osteoclastogenesis
by Sf-derived progenitors (data not shown).
More importantly, through Ab neutralization and genetic
ablation, we identified the critical role of M-CSF signaling
rather than IL-17 in this process. We demonstrate that the
commitment of HSCs is driven toward the macrophage/
preosteoclast lineage and ultimately results in increased
osteoclast formation and osteopenia. Our findings depict
important changes to characteristics of osteoclast progenitors
in the absence of immune surveillance. Specifically, LSK
HSCs derived from Sf bone marrow were highly potent
precursors and founders of osteoclasts. This finding can be
illustrated as more osteoclast precursors are present in Sf
LSKs and/or osteoclast precursors in the LSK pool are more
sensitive to osteoclastogenic stimuli. This is further supported
by our observations that more PU.1 LSKs and more GMPs
were present in Sf bone marrow. Interestingly, the pharmacologic and genetic approaches we conducted here to inhibit the
M-CSF/PI3K/mTOR axis markedly reduced the frequency of
GMPs in Sf bone marrow. These signals, as our findings
suggest, target the very primitive stage of hematopietic
progenitor cells.
The apparent myeloproliferation and abundance of osteoclast progenitors is consistent with higher expression of
M-CSF in Sf mice. This factor is obligatory for proliferation
and survival of osteoclast precursors, and genetic ablation of
the corresponding csf gene or its receptor c-fms obliterates
osteoclastogenesis and leads to osteopetrosis.27 Our findings
are supported by a recent report that demonstrated that under
inflammatory conditions, high expression of M-CSF induces
the myeloid master regulator PU.1 leading to changes in HSCs
cell fate and skewing myeloid differentiation.24 Hence,
modulating this pathway in Sf mice using pharmacologic and
genetic approaches relieved the osteoclastogenic burden and
significantly attenuated osteopenia in Sf mice. At the cellular
level, these M-CSF inhibitory approaches clearly attenuated
the increased frequency of the LSK and GMP cells in Sf mice
leading to decreased osteoclastogenesis.
M-CSF activates mTOR/PI3K/Akt pathway, and it has been
shown that rapamycin blocks M-CSF and RANKL-induced
osteoclastogenesis.28 Our study offers novel insights pointing
to inhibition of frequency of osteoclast progenitor pool by
rapamycin in Sf mice leading to amelioration of osteopenia.
Our findings suggest that mTOR signaling plays a key role in
mediating bone loss in Sf mice and highlight the significance of
M-CSF/mTOR/PI3K axis in autoimmune-mediated osteolytic
diseases. This concept is further supported by recent
evidence demonstrating significance of mTOR signaling in
joint destruction via robust osteoclast activity,29 thereby
positioning M-CSF signaling through mTOR as a significant
target to combat immune-mediated bone destruction.

Materials and Methods
Mice. C57/B6 WT, Sf and Op mice were obtained from Jackson Laboratories (Bar
Harbor, ME, USA). All mice were housed in CSRB NT or BJCIH animal facilities
under the guidelines of the Animal Studies Committee at Washington University
School of Medicine.
Cell Death and Disease
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Figure 6 Neutralization of M-CSF significantly rescued osteopenia in Sf mice. (a) Sf and WT mice were injected with M-CSF-neutralizing Ab or PBS as described in Material
and Methods. Cross-sections of femur bone extending from the growth plate were generated by 3-D reconstructed images through μCT analysis. BV/TV ratios were depicted as
bar graph. (b) Ex vivo osteoclastogenesis assay post in vivo administration of M-CSF-neutralizing Ab. (c) Flow cytometric analysis of WBM hematopoietic progenitors were
performed on WBMs derived from M-CSF Ab-administrated Sf mice with the rest of experimental control mice. Statistics for all bar graphs: n = 3 for WT group and n = 4 for Sf
group; *Po0.05 and **Po0.01 by Student T-test. Scale bars: 1 mm in (a); 200 μm in (b)

Structural and quantitative analysis of bone deformities. Long
bones were dissected from animals and fixed in 10% neutral buffered formalin for
2 days followed by three washes in PBS. Then muscle and connective tissues were
carefully removed from bone specimen before they were proceeded to experiments
or archived in 70% EtOH.
For μCT scan, long bone specimens were rehydrated with PBS and μCT scan was
performed. Long bone specimens were then retrieved from cylindrical vials, rehydrated
with PBS and placed in decalcifying solution for 7 days before histological analysis.
Histomorphometry was performed by TRAP staining on paraffin-embedded sections to
visualize osteoclasts lining on the bone surface followed by counterstained with H&E.
Assessment of cell-specific cytokine production. In vitro cell
stimulation and intracellular flow analysis for MACS-purified lymphocytes: bone
Cell Death and Disease

marrow- or spleen-derived CD4+ T-cells and CD8+ T-cells were purified by MACS
according to the manufacturer’s protocols. For stimulation of cytokine production,
500 000 purified cells were placed in modified complete RPMI media containing
5 μg/ml brefeldin A, 50 ng/ml PMA, 0.5 μg/ml ionomycin and cultured at 37 °C for
4 h. To assess cytokine production, stimulated cells were harvested into ice-old
PBS, washed and fixed according to eBiosciences (San Diego, CA, USA)
intracellular flow cytometry protocol before stained with anti-cytokine FACS
antibodies and analyzed on flow cytometer.
RNA isolation and qRT-PCR. Single mononucleated, red blood cell lysed
cell suspension derived from bone marrow, spleen, thymus or lymph nodes or
MACS-purified cells were lysed in Trizol reagent (Invitrogen, Carlsbad, CA, USA) for
isolation of total RNA. cDNA synthesis was performed from 1 ug of total RNA with a
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Figure 7 Rescue of the osteopenic phenotype in Sf via genetic ablation of M-CSF. (a) Representative μCT scanned 3-D images of the femur trabecular area of WT, Sf and
Op/+:: Sf mice. (b) Ex vivo osteoclastogenesis assay were performed using WBMs from WT, Sf, Op/+ and Op/+::Sf mice. (c) Frequency of LSK HSCs in Op/+ Sf mice using flow
cytometry. (d) Profile of megakaryocyte/erythroid progenitors/CMP/GMPs of WBMs derived from WT, Sf, Op/+ and Op/+ Sf mice, *Po0.05 and **Po0.01 by Student T-test.
Scale bars: 200 μm in (a and b)
mixture of random hexamers and poly-T oligos using Roche (Indianapolis, IN, USA)
cDNA synthesis kit. To assess the abundance of mRNA transcripts for cytokine or
transcription factors that mediate cytokine production, qPCR analysis was
performed with SYBR Green master mix (Bio-Rad, Hercules, CA, USA) with
primers corresponding to the gene of interest. GAPDH, tubulin or Cyclophilin A
gene expression was monitored as endogenous control. All real-time PCR reactions
were run on BioRad’s CFX96 Real-Time System.
Multiplex cytokine/chemokine profiling for serum. Mouse peripheral
blood was collected in Microtainer serum separator tube (BD Bioscience, Franklin
Lakes, NJ, USA) before centrifugation to obtain serum. All serum samples were
archived in − 80 °C freezer before being subjected to cytokine/chemokine
measurement.
Multiplex cytokine/chemokine assay was performed according to the manufacturer’s protocol (Millipore, St Charles, MO, USA). Briefly, 25 ul serum samples were
loaded onto the 32-plex Mouse Cytokine/Chemokine Magnetic Bead Panel 96-well
plate (MCYTOMAG-70 K-PX32). Following the incubation with 25 ul of magnetic
beads at 4 °C overnight, biotin-conjugated antibodies and PE-conjugated streptavidin
were subsequently added before the plate was processed with an automated washer
and analyzed on a Bioplex system (Bio-Rad)
Ex vivo osteoclast proliferation and differentiation assay
BrdU flow assay: After being cultured overnight on petridish with 1/50 diluted
CMG, stromal cells were removed from WBM culture by re-plating suspension cells
on tissue culture-treated plates to initiate macrophage culture. BrdU was added to
macrophage culture with or without the presence of RANKL (50 ng/ml) for 4 days.

For BrdU flow assay, cells were detached by Accutase and fixed with Foxp3 fix/perm
buffer after washing with PBS. Fixed cells were permeabilized, digested with
DNAase I, labeled with Alexa647-conjugated anti-BrdU Ab, washed and
resuspended in the presence of 7-AAD before analyzing on a flow cytometer.
Assessment and quantification of osteoclast formation: After removal of
adherent stromal cells, WBM cells were plated on 96-well microplates at a series of
seeding densities from 200 000, 100 000, 50 000, 25 000, 12 500 and 6250 per well
(or as otherwise mentioned). After stimulation with RANKL for 3–4 days, fixation and
TRAP staining was performed to visualize multinucleated osteoclasts using the
Leukocyte Acid Phosphatase kit from Sigma (St. Louis, MO, USA). Cultures without
the presence of RANKL were served as the negative control.
FACS-based profiling for hematopoietic progenitor cells, osteoclast progenitors and myeloid lineage cells. For assessment of
hematopoietic progenitor cells in the bone marrow, WBMs were suspended in FACS
buffer at the maximum concentration of 10 million cells per 100 ul and stained with
biotin-conjugated lineage Ab cocktail (anti-B220, anti-CD3e, anti-Gr1, anti-Ter119
and anti-CD41) and HSC Ab cocktail (anti-Sca1 PerCP Cy5.5, anti-c-Kit APC eFluor
780, anti-CD34 FITC, anti-FLK2 APC, anti-CD48 PE Cy7, anti-CD150 PE and
CD16/32 eFluor450) before red cell lysis. All FACS antibodies were purchase from
either eBioscience, BioLegend (San Diego, CA, USA) or BD Bioscience (San Diego,
CA, USA). Following incubation on ice for 45 min, Ab-labeled cells were washed
twice with cold FACS buffer and either fixed with 2% PFA or immediately subjected
to flow cytometric analysis.
Cell Death and Disease
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Figure 8 In vivo administration of rapamycin ameliorated osteopenia in Sf mice through reduction of osteoclastogenic activity in the bone marrow. (a) Representative images
from μCT analysis of rapamycin versus vehicle-treated Sf mice. (b) Trabecular BV/TV values of vehicle- and rapamycin-treated mice. (c) Ex vivo osteoclastogenesis assay.
(d) Hematopoietic progenitor cell profiling by flow cytometry depicting megakaryocyte/erythroid progenitors, CMP and GMP cells from the various experimental groups described
in panel a. Statistics for all bar graphs: n = 4 for per group; *Po0.05 and **Po0.01 by Student T-test. Scale bars: Scale bars: 200 μm in (a and c)

MACS and FACS sorting of bone marrow subpopulations for
ex vivo osteoclastogenesis assay. To obtain lineage-negative CD11b+
and CD11b- cells, WBM cells were red cell-lysed, first labeled with biotin-conjugated
lineage antibodies and then incubated with anti-biotin magnetic microbeads to
deplete lineage cells. Anti-CD11b microbeads was subsequently used to separate
CD11b+ from CD11b- cells. These MACS-purified cells were subjected to
osteoclastogenesis assay as routinely done for WBMs or bone marrow
macrophages, except they were seeded at a much lower series of density to
obtain the optimal number of multinucleated osteoclast formation. MDSC isolation
kit was used to obtain bone marrow cells that immuno-phenotypically
resembled MDSCs.
For isolation of LSK HSCs, CMPs and GMPs, WBM cells were labeled with FACS
antibodies as described above for progenitor analysis and sorted by either Sony
Synergy (Sony Biotechnology, San Jose, CA, USA) or MoFlo sorter (Beckman
Coulter, Indianapolis, IN, USA). These progenitor cells were sorted into ice-old culture
alpha MEM supplemented with 20% FBS to maximize their survival rate. After sorting,
cell counts were determined after resuspending cell pellets in a small volume of
culture media before plating on 96-well microplates for osteoclastogenesis assay.
Osteoclast founder cell assay. FACS-sorted HSCs, CMPs and GMPs
were mixed with WBM cells at 1 : 9 ratio before subjecting to osteoclastogenesis
assay. To test their sensitivity to M-CSF, recombinant M-CSF (Peprotech, Rocky Hill,
NJ, USA) instead of CMG was used in the culture, and standard ex vivo
osteoclastogenesis protocol was followed.
Cell Death and Disease

Neutralizing Ab anti-M-CSF. Seven-day-old mice were i.p. injected with
M-CSF neutralizing Ab (Bio X Cell, West Lebanon, NH, USA) twice a week for
3 weeks before killing for end-point analysis. Control mice were injected with equal
volume of sterile PBS in parallel.
Pathway inhibitors. Rapamycin working solution was prepared by diluting
10 mg/ml stock solution with 5% Tween80/5% PEG-400 by fivefold. Seven-day-old
mice were then i.p. injected with 20 ug rapamycin through a 25 ul Hamilton syringe
(Hamilton Co., Reno, NV, USA). Mice were re-administered five more times for the
course of 3 weeks before end-point analysis. Control mice were injected with the
vehicle solution.
Western blot analysis and co-immunoprecipitation. For sample
preparation, primary tissues (e.g., bone marrow, spleen, lymph nodes, thymus,
peritoneal cavity) were processed into single mononuclear cell suspension after
red blood cells were removed. To obtain protein lysates for western analysis,
CLB buffer was used. For co-immunoprecipitation studies, RIPA buffer was used
instead. Lamieli sample buffer (5 × ) was added to each protein lysate with
β-mercaptoethanol before boiling for 5 min for protein denaturation and reduction.
Samples were then resolved on 8% SDS-PAGE gels, blotted on PVDF membranes
using Bio-Rad’s Trans-Blot Turbo system before probes with antibodies.
Luciferase NF-κB reporter assay. 293T cells were co-transfected with
Luciferase reporter and Renillia luciferase plasmids with pcDNA plasmids carrying
NEMO and Foxp3 cDNA. Renilla luciferase activity was used as internal loading
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control. Luficerase activity was assessed by Promega’s Stop-and-Go system. For
each sample, Luciferase activity was normalized by Renilla luciferase activity.

Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. This work was supported by grants from the Shriners
Hospital for Children (grant 85600) and the National Institute of Health (grant
# AR054326, AR049192) to YA.

1. Harada S-i, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature
2003; 423: 349–355.
2. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol 2007; 170:
427–435.
3. Xing L, Schwarz EM, Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology.
Immunol Rev 2005; 208: 19–29.
4. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance.
Cell 2008; 133: 775–787.
5. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007;
8: 457–462.
6. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA et al. Disruption of a
new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of
the scurfy mouse. Nat Genet 2001; 27: 68–73.
7. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription
factor Foxp3. Science 2003; 299: 1057–1061.
8. Sharma R, Sharma PR, Kim YC, Leitinger N, Lee JK, Fu SM et al. IL-2-controlled expression
of multiple T cell trafficking genes and Th2 cytokines in the regulatory T cell-deficient scurfy
mice: implication to multiorgan inflammation and control of skin and lung inflammation.
J Immunol 2011; 186: 1268–1278.
9. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J et al. Osteoimmunology:
interplay between the immune system and bone metabolism. Annu Rev Immunol 2006; 24:
33–63.
10. Caetano-Lopes J, Canhao H, Fonseca JE. Osteoimmunology–the hidden immune regulation
of bone. Autoimmun Rev 2009; 8: 250–255.
11. Kong Y, Fiege U, Sarosi I, Bolon B, Tafuri A, Morony S et al. Activated T cells regulate bone
loss and joint destruction in adjuvant arthritis through osteoprotegrin ligand. Nature 1999;
402: 304–309.
12. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K et al. T-cell-mediated
regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
Nature 2000; 408: 600–605.
13. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y et al. Th17 functions
as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction.
J Exp Med 2006; 203: 2673–2682.
14. Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of
NF-kappaB. J Clin Invest 2001; 107: 1375–1385.
15. Zaiss MM, Sarter K, Hess A, Engelke K, Böhm C, Nimmerjahn F et al. Increased bone
density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on
impaired osteoclast differentiation. Arthritis Rheum 2010; 62: 2328–2338.

16. Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and
NF-κB to repress cytokine gene expression and effector functions of T helper cells. Proc Natl
Acad Sci USA 2005; 102: 5138–5143.
17. Zaiss MM, Axmann R, Zwerina J, Polzer K, Guckel E, Skapenko A et al. Treg cells suppress
osteoclast formation: a new link between the immune system and bone. Arthritis Rheum
2007; 56: 4104–4112.
18. Kim YG, Lee CK, Nah SS, Mun SH, Yoo B, Moon HB. Human CD4+CD25+ regulatory T cells
inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells. Biochem
Biophys Res Commun 2007; 357: 1046–1052.
19. Ramsdell F, Ziegler SF. FOXP3 and scurfy: how it all began. Nat Rev Immunol 2014; 14:
343–349.
20. Abu-Amer Y. NF-κB signaling and bone resorption. Osteoporos Int 2013; 24:
2377–2386.
21. Sawant A, Deshane J, Jules J, Lee CM, Harris BA, Feng X et al. Myeloid-derived suppressor
cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer
Res 2013; 73: 672–682.
22. Charles JF, Hsu LY, Niemi EC, Weiss A, Aliprantis AO, Nakamura MC. Inflammatory arthritis
increases mouse osteoclast precursors with myeloid suppressor function. J Clin Invest 2012;
122: 4592–4605.
23. King KY, Goodell MA. Inflammatory modulation of HSCs: viewing the HSC as a foundation
for the immune response. Nature Rev Immunol 2011; 11: 685–692.
24. Mossadegh-Keller N, Sarrazin S, Kandalla PK, Espinosa L, Stanley ER, Nutt SL et al. M-CSF
instructs myeloid lineage fate in single haematopoietic stem cells. Nature 2013; 497:
239–243.
25. Mario M Zaiss, Axmann Roland, Zwerina Jochen, Polzer Karin, Gückel Eva, Skapenko Alla
et al. Treg cells suppress osteoclast formation: A new link between the immune system
and bone. Arthritis Rheum 2007; 56: 4104–4112.
26. Schett G, David JP. The multiple faces of autoimmune-mediated bone loss. Nat Rev
Endocrinol 2010; 6: 698–706.
27. Yoshida H, Hayashi S-I, Kunisada T, Ogawa M, Nishikawa S, Okamura H et al. The murine
mutation osteopetrosis is in the coding region of the macrophage colony stimulating
factor gene. Nature 1990; 345: 442–443.
28. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNF[alpha] and
RANK ligand promote osteoclast survival by signaling through mTOR//S6 kinase. Cell Death
Differ 2003; 10: 1165–1177.
29. Cejka D, Hayer S, Niederreiter B, Sieghart W, Fuereder T, Zwerina J et al. Mammalian
target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is
activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum 2010; 62:
2294–2302.

Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from
the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)

Cell Death and Disease

